Trial Profile

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 1292263 (Primary) ; Atorvastatin; Ezetimibe
Indications Dyslipidaemias
Focus Adverse reactions; Therapeutic Use
Sponsors GlaxoSmithKline; GSK

Most Recent Events

07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
12 Aug 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
12 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com